查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951856

肿瘤精准医疗市场分析及预测（至2035年）：类型、产品类型、服务、技术、应用、最终用户、组件、实施类型、解决方案与阶段

Oncology Precision Medicine Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Deployment, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 359 Pages | 商品交期: 3-5个工作天内

价格
简介目录

肿瘤精准医疗市场预计将从2024年的613亿美元成长到2034年的1,591亿美元，复合年增长率约为9.4%。肿瘤精准医疗市场涵盖了针对个人基因谱量身定制的标靶治疗和诊断技术，旨在提高治疗效果并减少副作用。基因组学、生物资讯学和个人化医疗的进步推动了该市场的发展，使得癌症突变的精准识别成为可能。癌症发病率的上升和对个人化治疗的需求正在推动生物标记发现和伴随诊断技术的创新，从而促进市场成长。

癌症精准医疗市场正经历强劲成长，这主要得益于个人化治疗方法和分子诊断技术的进步。诊断领域是推动市场发展的关键力量，其中次世代定序和液态生物检体技术在癌症的早期精准检测中发挥着至关重要的作用。特别是次世代定序，因其全面的基因组分析能力而备受关注。治疗药物领域也紧随其后，标靶治疗和免疫疗法正在改变癌症治疗模式。在治疗药物领域，标靶治疗是表现最佳的细分市场，它提供的个人化治疗方案能够改善患者的治疗效果。免疫疗法是表现第二好的细分市场，这反映了其利用人体自体免疫系统攻击癌症的潜力。伴随诊断也日益受到关注，它有助于根据个别基因谱选择合适的治疗方法。人工智慧（AI）和机器学习在精准医疗中的应用进一步提升了预测分析和治疗效果。製药公司与研究机构之间的策略联盟和合作研究正在加速创新并拓展市场潜力。

市场区隔
类型 治疗方法和诊断方法
产品 伴随诊断、生物标记检测套组和基因组分析工具
服务 遗传咨询、检测服务和数据解读服务
科技 次世代定序、聚合酵素链锁反应、原位杂合反应、免疫组织化学、液态生物检体
适应症 乳癌、肺癌、结肠癌、摄护腺癌
最终用户 医院、诊断检查室、研究机构、製药公司
成分 软体、硬体
实施表格 本机部署、云端部署
解决方案 临床决策支援、数据管理和预测分析
步 早期诊断，晚期治疗

在肿瘤精准医疗市场，主要企业正透过策略定价和创新产品推出不断扩大市场份额。丰富的新型治疗方法和诊断工具研发管线正在推动市场竞争，并改善治疗效果。各公司专注于根据特定基因谱客製化个人化解决方案，以优化患者预后。这种充满活力的市场环境促进了合作与伙伴关係的建立，而合作与伙伴关係对于加速研发至关重要。竞争基准研究揭示了高度竞争的市场环境，主要参与者正透过策略联盟和併购来争夺主导。监管影响发挥关键作用，严格的指导方针塑造着产品开发和打入市场策略。监管核准的增加促进了最先进治疗的应用。随着技术进步和人工智慧的融合革新患者照护，竞争格局进一步加剧。随着市场的发展，相关人员必须应对复杂的监管环境，并利用技术创新来保持竞争优势。

主要趋势和驱动因素：

肿瘤精准医疗市场正经历强劲成长，这主要得益于基因组技术和个人化治疗方法的进步。其中一个关键趋势是将人工智慧 (AI) 和机器学习应用于数据分析，从而提高癌症诊断和治疗方案製定的准确性。这些技术能够识别新的生物标记和治疗靶点，促进个人化医疗的有效性和广泛应用。另一个重要趋势是製药公司与研究机构之间合作的加强。这种协同作用正在加速药物研发进程，并开发出针对个体基因谱的创新治疗方法。癌症发病率的上升和对标靶治疗解决方案的核准流程，以加速其市场准入。新兴市场拥有不断完善的医疗基础设施和日益增强的精准医疗意识，蕴藏着许多机会。投资研发并建立策略联盟的公司能够更好地利用这些趋势，推动市场成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 治疗方法
    • 诊断
  • 市场规模及预测：依产品划分
    • 伴随诊断
    • 生物标记检测套组
    • 基因组分析工具
  • 市场规模及预测：依服务划分
    • 遗传咨询
    • 检查服务
    • 数据解读服务
  • 市场规模及预测：依技术划分
    • 次世代定序
    • 聚合酵素链锁反应
    • 原位杂合反应
    • 免疫组织化学
    • 液态生物检体
  • 市场规模及预测：依应用领域划分
    • 乳癌
    • 肺癌
    • 大肠直肠癌
    • 摄护腺癌
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊断检查室
    • 研究所
    • 製药公司
  • 市场规模及预测：依组件划分
    • 软体
    • 硬体
  • 市场规模及预测：依发展状况
    • 本地部署
    • 基于云端的
  • 市场规模及预测：按解决方案划分
    • 临床决策支持
    • 资料管理
    • 预测分析
  • 市场规模及预测：依疾病阶段划分
    • 早期诊断
    • 晚期治疗

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Foundation Medicine
  • Guardant Health
  • Caris Life Sciences
  • Tempus
  • Natera
  • Neo Genomics
  • Personalis
  • Adaptive Biotechnologies
  • Freenome
  • GRAIL
  • Oncocyte Corporation
  • Invitae
  • Biodesix
  • Strata Oncology
  • Exact Sciences
  • Illumina
  • Blueprint Medicines
  • Loxo Oncology
  • Myriad Genetics
  • Molecular MD

第九章：关于我们

简介目录
Product Code: GIS31514

Oncology Precision Medicine Market is anticipated to expand from $61.3 billion in 2024 to $159.1 billion by 2034, growing at a CAGR of approximately 9.4%. The Oncology Precision Medicine Market encompasses targeted therapies and diagnostics tailored to individual genetic profiles, enhancing treatment efficacy and reducing adverse effects. This market is driven by advances in genomics, bioinformatics, and personalized healthcare, enabling precise identification of cancer mutations. Increasing cancer prevalence and demand for personalized treatment are propelling growth, encouraging innovations in biomarker discovery and companion diagnostics.

The Oncology Precision Medicine Market is experiencing robust growth, driven by advancements in personalized treatment approaches and molecular diagnostics. The diagnostics segment leads in performance, with next-generation sequencing and liquid biopsy technologies being pivotal in early and accurate cancer detection. Among these, next-generation sequencing stands out due to its comprehensive genomic profiling capabilities. The therapeutics segment follows closely, with targeted therapies and immunotherapies revolutionizing cancer treatment paradigms. Within therapeutics, targeted therapies are the top-performing sub-segment, offering personalized treatment options that improve patient outcomes. Immunotherapies are the second highest-performing sub-segment, reflecting their potential in harnessing the body's immune system to combat cancer. Companion diagnostics are gaining traction, facilitating the selection of appropriate therapies based on individual genetic profiles. The integration of artificial intelligence and machine learning in precision medicine is further enhancing predictive analytics and treatment efficacy. Strategic partnerships and collaborations among pharmaceutical companies and research institutions are accelerating innovation and expanding the market's potential.

Market Segmentation
TypeTherapies, Diagnostics
ProductCompanion Diagnostics, Biomarker Testing Kits, Genomic Profiling Tools
ServicesGenetic Counseling, Laboratory Services, Data Interpretation Services
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry, Liquid Biopsy
ApplicationBreast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
End UserHospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies
ComponentSoftware, Hardware
DeploymentOn-premise, Cloud-based
SolutionsClinical Decision Support, Data Management, Predictive Analytics
StageEarly-stage Diagnosis, Advanced-stage Treatment

In the Oncology Precision Medicine Market, leading companies are expanding their market share through strategic pricing and innovative product launches. The landscape is characterized by a robust pipeline of novel therapies and diagnostic tools, driving competition and enhancing treatment efficacy. Companies are focusing on personalized solutions that address specific genetic profiles, thus optimizing patient outcomes. This dynamic environment is fostering collaborations and partnerships, which are pivotal in accelerating research and development efforts. Competition benchmarking reveals a highly competitive arena with key players vying for dominance through strategic alliances and mergers. Regulatory influences play a significant role, with stringent guidelines shaping product development and market entry strategies. The market is witnessing increased regulatory approvals, facilitating the introduction of cutting-edge therapies. The competitive landscape is further intensified by technological advancements and the integration of artificial intelligence, which are revolutionizing patient care. As the market evolves, stakeholders must navigate regulatory complexities and leverage technological innovations to maintain a competitive edge.

Geographical Overview:

The Oncology Precision Medicine Market is witnessing substantial growth across various regions, each with unique dynamics. North America leads, fueled by advanced healthcare infrastructure and significant investments in personalized medicine. The presence of major biotech firms and cutting-edge research institutions further propels the market's expansion. Europe follows closely, with strong governmental support for precision medicine initiatives and a robust regulatory framework that promotes innovation. Asia Pacific is emerging as a key growth pocket, driven by increasing healthcare expenditure and the rising prevalence of cancer. Countries like China and India are investing heavily in precision medicine research, fostering a conducive environment for market growth. Latin America and the Middle East & Africa are also showing promising potential. Brazil and Mexico are notable for their expanding healthcare sectors, while the Middle East & Africa are recognizing the importance of precision medicine in addressing regional health challenges and improving patient outcomes.

Global tariffs and geopolitical tensions are significantly impacting the Oncology Precision Medicine Market, particularly in East Asia. Japan and South Korea are navigating trade barriers by enhancing domestic R&D in precision oncology, aiming to reduce dependency on foreign technologies. China's strategy focuses on fostering indigenous innovation amidst export restrictions, while Taiwan continues to leverage its semiconductor prowess, albeit with heightened geopolitical risks. The parent market is witnessing robust growth driven by advancements in genomics and personalized therapies, yet is vulnerable to supply chain disruptions. By 2035, the market is anticipated to evolve with increased regional collaborations and technological self-reliance. Middle East conflicts exacerbate these challenges by influencing energy prices, thereby affecting manufacturing and logistics costs globally.

Key Trends and Drivers:

The Oncology Precision Medicine Market is experiencing robust expansion, fueled by advancements in genomic technologies and personalized treatment approaches. A key trend is the integration of artificial intelligence and machine learning in data analysis, enhancing the accuracy of cancer diagnosis and treatment plans. These technologies enable the identification of novel biomarkers and therapeutic targets, driving personalized medicine's effectiveness and adoption. Another significant trend is the growing collaboration between pharmaceutical companies and research institutions. This synergy accelerates drug discovery and development processes, resulting in innovative therapies tailored to individual genetic profiles. The increasing prevalence of cancer and the demand for targeted therapies further propel market growth. Precision medicine reduces adverse effects and improves patient outcomes, making it an attractive option for healthcare providers. Moreover, government initiatives and funding for cancer research are creating a conducive environment for market development. Regulatory bodies are streamlining approval processes for precision medicine solutions, facilitating faster market entry. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and awareness of precision medicine is rising. Companies that invest in research and development, while forming strategic partnerships, are well-positioned to capitalize on these trends and drive market growth.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Therapies
    • 4.1.2 Diagnostics
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Companion Diagnostics
    • 4.2.2 Biomarker Testing Kits
    • 4.2.3 Genomic Profiling Tools
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genetic Counseling
    • 4.3.2 Laboratory Services
    • 4.3.3 Data Interpretation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 In Situ Hybridization
    • 4.4.4 Immunohistochemistry
    • 4.4.5 Liquid Biopsy
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Breast Cancer
    • 4.5.2 Lung Cancer
    • 4.5.3 Colorectal Cancer
    • 4.5.4 Prostate Cancer
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Software
    • 4.7.2 Hardware
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 On-premise
    • 4.8.2 Cloud-based
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Clinical Decision Support
    • 4.9.2 Data Management
    • 4.9.3 Predictive Analytics
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Early-stage Diagnosis
    • 4.10.2 Advanced-stage Treatment

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Deployment
      • 5.2.1.9 Solutions
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Deployment
      • 5.2.2.9 Solutions
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Deployment
      • 5.2.3.9 Solutions
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Deployment
      • 5.3.1.9 Solutions
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Deployment
      • 5.3.2.9 Solutions
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Deployment
      • 5.3.3.9 Solutions
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Deployment
      • 5.4.1.9 Solutions
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Deployment
      • 5.4.2.9 Solutions
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Deployment
      • 5.4.3.9 Solutions
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Deployment
      • 5.4.4.9 Solutions
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Deployment
      • 5.4.5.9 Solutions
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Deployment
      • 5.4.6.9 Solutions
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Deployment
      • 5.4.7.9 Solutions
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Deployment
      • 5.5.1.9 Solutions
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Deployment
      • 5.5.2.9 Solutions
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Deployment
      • 5.5.3.9 Solutions
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Deployment
      • 5.5.4.9 Solutions
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Deployment
      • 5.5.5.9 Solutions
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Deployment
      • 5.5.6.9 Solutions
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Deployment
      • 5.6.1.9 Solutions
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Deployment
      • 5.6.2.9 Solutions
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Deployment
      • 5.6.3.9 Solutions
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Deployment
      • 5.6.4.9 Solutions
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Deployment
      • 5.6.5.9 Solutions
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Foundation Medicine
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Guardant Health
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Caris Life Sciences
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Tempus
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Natera
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Neo Genomics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Personalis
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Adaptive Biotechnologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Freenome
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 GRAIL
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Oncocyte Corporation
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Invitae
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Biodesix
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Strata Oncology
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Exact Sciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Illumina
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Blueprint Medicines
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Loxo Oncology
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Myriad Genetics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Molecular MD
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us